Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comment on: Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV.
Benaboud S, Solas C, Bouchet S, Gregoire M, Lemaitre F, Venisse N, Lê MP, Muret P, Parant F, Neant N, Boujafaar S, Lagoutte-Renosi J, Garraffo R, Peytavin G. Benaboud S, et al. Among authors: garraffo r. J Antimicrob Chemother. 2023 Mar 2;78(3):853-854. doi: 10.1093/jac/dkad009. J Antimicrob Chemother. 2023. PMID: 36683308 No abstract available.
Lopinavir/ritonavir combination and total/HDL cholesterol ratio.
Valerio L, Fontas E, Pradier C, Lavrut T, Garraffo R, Dunais B, Cua E, Dellamonica P. Valerio L, et al. Among authors: garraffo r. J Infect. 2005 Apr;50(3):229-35. doi: 10.1016/j.jinf.2004.01.014. J Infect. 2005. PMID: 15780417
Fluconazole therapy for Candida albicans urinary tract infections in infants.
Triolo V, Gari-Toussaint M, Casagrande F, Garraffo R, Dageville C, Boutté P, Bérard E. Triolo V, et al. Among authors: garraffo r. Pediatr Nephrol. 2002 Jul;17(7):550-3. doi: 10.1007/s00467-002-0861-y. Epub 2002 Jun 21. Pediatr Nephrol. 2002. PMID: 12172774 Clinical Trial.
Pharmacokinetic interaction between maraviroc and etravirine in HIV-infected patients receiving regimens containing both drugs and no ritonavir-boosted protease inhibitor.
Lê MP, Solas C, Garraffo R, Gagnieu MC, Muret P, Yeni P, Dhiver C, Katlama C, Poizot-Martin I, Durant J, Peytavin G. Lê MP, et al. Among authors: garraffo r. J Antimicrob Chemother. 2012 Nov;67(11):2779-81. doi: 10.1093/jac/dks260. Epub 2012 Jul 6. J Antimicrob Chemother. 2012. PMID: 22773742 No abstract available.
Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.
Poizot-Martin I, Bellissant E, Garraffo R, Colson P, Piroth L, Solas C, Renault A, Bourlière M, Halfon P, Ghosn J, Alric L, Naqvi A, Carrieri P, Molina JM; ANRS HC27 BOCEPREVIH Study Group. Poizot-Martin I, et al. Among authors: garraffo r. HIV Clin Trials. 2016 Mar;17(2):63-71. doi: 10.1080/15284336.2015.1135553. Epub 2016 Feb 11. HIV Clin Trials. 2016. PMID: 27077673 Free article. Clinical Trial.
ITPA deficiency and ribavirin level are still predictive of anaemia in HCV-HIV-coinfected patients receiving ribavirin combined with a first-generation DAA (ANRS HC27 study).
Kheloufi F, Poizot-Martin I, Garraffo R, Tavenard A, Quaranta S, Renault A, Lavrut T, Bourlière M, Halfon P, Piroth L, Bellissant E, Lacarelle B, Molina JM, Solas C; ANRS HC27 BOCEPREVIH Study Group. Kheloufi F, et al. Among authors: garraffo r. Antivir Ther. 2017;22(6):461-469. doi: 10.3851/IMP3074. Epub 2016 Sep 1. Antivir Ther. 2017. PMID: 27583701
145 results